Fig. 7From: STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathwaySchematic representation of the role of STAT3 in prostate cancer. In a mouse model of PCa with PTEN loss, deletion of STAT3 results in decreased levels of LKB1/pAMPK but increased activation of mTOR signaling, leading to the development of mPCa. In contrast, constitutively activation of STAT3 results in high levels of LKB1/pAMPK and decreased activity of the mTORC1/CREB pathway, thus, preventing the development of cancer in mice with PTEN lossBack to article page